| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | TL-2-105 | GDSC1000 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | PHA-793887 | GDSC1000 | pan-cancer | AAC | 0.034 | 0.2 |
| mRNA | lenalidomide | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | CHM-1 | CTRPv2 | pan-cancer | AAC | 0.039 | 0.2 |
| mRNA | cabozantinib | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | RAF265 | FIMM | pan-cancer | AAC | -0.21 | 0.2 |
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.065 | 0.2 |
| mRNA | triazolothiadiazine | CTRPv2 | pan-cancer | AAC | 0.036 | 0.2 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.045 | 0.2 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.065 | 0.2 |